|Bid||268.80 x 1300|
|Ask||277.80 x 1000|
|Day's Range||272.00 - 277.20|
|52 Week Range||170.02 - 325.54|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||116.87|
|Earnings Date||May 26, 2021 - May 31, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||328.36|
Parexel and Veeva Systems (NYSE: VEEV) today announced a strategic collaboration to accelerate clinical trials through technology and process innovation. The unique collaboration combines the best of each company's experience across thousands of studies worldwide – Parexel as a leading clinical research organization (CRO) and Veeva as the technology innovator powering trials – to improve study efficiency and get new therapies to patients faster.
Veeva Systems (NYSE: VEEV), Cerner (NASDAQ: CERN), and Merck (NYSE: MRK) offer investors different reasons to buy their stocks. The best stock is one that you're comfortable holding for the long term, avoiding emotional decisions when the market is volatile. The company was founded on the idea that software built to solve the problems of only one industry could lead to a better product.
At Insider Monkey, we pore over the filings of nearly 887 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of December 31st. In this […]